Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Teva Pharmaceutical Industries has a consensus analyst rating of “Moderate Buy”, with 9 of 10 analysts recommending buy and an average 12-month price target of about $41.78.
• Several brokerages recently raised price targets on Teva, including Goldman Sachs to $45, Barclays to $40, JPMorgan to $40, and Bank of America to $42, signaling improving sentiment.
• The stock last traded at $34.60, above its 50-day and 200-day moving averages, while the company reported $0.53 EPS on $3.98 billion in quarterly revenue and continues to see notable insider share sales.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $41.7778.

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group upped their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. Barclays upped their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 6th. Wall Street Zen lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an "overweight" rating in a research note on Thursday, April 30th. Finally, Bank of America lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday, April 9th.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $34.60 on Thursday. The firm has a market cap of $39.78 billion, a price-to-earnings ratio of 26.01, a price-to-earnings-growth ratio of 3.35 and a beta of 0.86. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The business has a 50-day moving average price of $32.15 and a 200-day moving average price of $31.23. Teva Pharmaceutical Industries has a twelve month low of $14.99 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, equities research analysts predict that Teva Pharmaceutical Industries will post 2.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the sale, the executive vice president owned 172,184 shares of the company's stock, valued at $6,131,472.24. The trade was a 47.09% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the sale, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. The trade was a 34.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 934,459 shares of company stock worth $31,122,931. Insiders own 0.54% of the company's stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of large investors have recently added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $25,000. Cornerstone Planning Group LLC lifted its stake in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock valued at $27,000 after purchasing an additional 755 shares during the last quarter. Allworth Financial LP raised its holdings in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company's stock valued at $29,000 after buying an additional 329 shares during the period. Grove Bank & Trust raised its holdings in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company's stock valued at $31,000 after buying an additional 750 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company's stock valued at $32,000 after buying an additional 345 shares during the period. Institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.